In recent years, technological innovations in the field of molecular biology have provided new therapeutic options. In particular, human monoclonal antibodies (mAbs), initially used in the treatment of malignancies, have become a therapeutic tool for many other diseases. Most of the application of mAbs revealed encouraging findings to treat patients with immune-mediated glomerular diseases, for whom the standard protocols based on corticosteroids and non-specific immunosuppressants with heavy side effects have for decades been the only therapies.

Monoclonal antibodies for renal diseases: current concepts and ongoing treatments

Trifirò, Gianluca;
2015-01-01

Abstract

In recent years, technological innovations in the field of molecular biology have provided new therapeutic options. In particular, human monoclonal antibodies (mAbs), initially used in the treatment of malignancies, have become a therapeutic tool for many other diseases. Most of the application of mAbs revealed encouraging findings to treat patients with immune-mediated glomerular diseases, for whom the standard protocols based on corticosteroids and non-specific immunosuppressants with heavy side effects have for decades been the only therapies.
Glomerulonephritis
Monoclonal
Proteinuria
Renal disease
File in questo prodotto:
File Dimensione Formato  
2015 Expert Opin Biol Ther -Monoclonal in renal diseases.pdf

non disponibili

Dimensione 425.75 kB
Formato Adobe PDF
425.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Santoro_trifirò_Monoclonal.pdf

non disponibili

Dimensione 8.61 MB
Formato Adobe PDF
8.61 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1039510
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact